{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:11:29Z","timestamp":1793171489895,"version":"4.5.0"},"reference-count":98,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"<jats:sec id=\"ab-jrv250032-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Peripheral neuropathy, defined as damage to peripheral nerves, affects approximately 1% of adults worldwide. More than 200 causes of peripheral neuropathy exist, with symptoms ranging in severity from mild toe numbness to debilitating symptoms that can require a wheelchair. Diabetes is the most common cause of neuropathy, affecting approximately 206 million people worldwide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250032-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      Peripheral neuropathy is typically length-dependent, which means that symptoms appear in the longest nerve axons (toes) and progress proximally over time. Peripheral neuropathy is typically symmetric and affects sensory axons more than motor axons. Diabetic neuropathy, which is often associated with both sensory symptoms, such as pain, tingling, or numbness; mild weakness; and autonomic symptoms, such as orthostatic hypotension, accounts for more than 50% of peripheral neuropathy in Western populations. Other causes of neuropathy include hereditary causes, such as Charcot-Marie-Tooth disease, toxic neuropathy from medications (chemotherapies [eg, cisplatin, paclitaxel, vincristine], amiodarone, or HIV nucleotide reverse transcriptase inhibitors [eg, stavudine, zalcitabine]); alcohol; vitamin deficiencies such as vitamin B\n                      <jats:sub>12<\/jats:sub>\n                      ; and monoclonal gammopathies. Up to 27% of adults with neuropathy have no identifiable etiology for their neuropathy after diagnostic testing. Recommended initial testing includes blood glucose (for diabetes), serum B\n                      <jats:sub>12<\/jats:sub>\n                      with metabolites (methylmalonic acid with or without homocysteine), and serum protein electrophoresis with immunofixation (for monoclonal gammopathies). First-line medications for neuropathic pain are the \u03b12-\u03b4 calcium channel subunit ligands, such as gabapentin and pregabalin; serotonin norepinephrine reuptake inhibitors, such as duloxetine and venlafaxine; and tricyclic antidepressants, such as amitryptyline and nortriptyline. Pain often persists despite medical management. At least a 50% reduction in pain was observed in 38% of those with painful diabetic peripheral neuropathy receiving 1200 mg of gabapentin daily. Combination drug therapies for neuropathic pain may provide added benefit. The prognosis of peripheral neuropathy depends on its underlying cause, but complete reversal of nerve damage is uncommon even in cases for which there are available treatments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250032-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Peripheral neuropathy affects approximately 1% of adults worldwide and may cause sensory, motor, and autonomic symptoms. Diabetes is the most common cause of peripheral neuropathy in Western countries. First-line therapies for neuropathic pain include gabapentin, pregabalin, duloxetine, and amitriptyline.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.19400","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T16:31:08Z","timestamp":1763397068000},"page":"255","source":"Crossref","is-referenced-by-count":68,"title":["Peripheral Neuropathy"],"prefix":"10.1001","volume":"335","author":[{"given":"Michelle L.","family":"Mauermann","sequence":"first","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan P.","family":"Staff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"jrv250032r1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10654-015-0094-6","article-title":"The epidemiology and risk factors of chronic polyneuropathy.","volume":"31","author":"Hanewinckel","year":"2016","journal-title":"Eur J Epidemiol"},{"issue":"16","key":"jrv250032r2","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1212\/WNL.0000000000001492","article-title":"Impairments and comorbidities of polyneuropathy revealed by population-based analyses.","volume":"84","author":"Hoffman","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"jrv250032r3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","article-title":"Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"23","author":"Collaborators","year":"2024","journal-title":"Lancet Neurol"},{"issue":"6","key":"jrv250032r4","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1473-3099(11)70006-8","article-title":"Leprosy now: epidemiology, progress, challenges, and research gaps.","volume":"11","author":"Rodrigues","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"jrv250032r5","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1248922","article-title":"Neuron-Schwann cell interactions in peripheral nervous system homeostasis, disease, and preclinical treatment.","volume":"17","author":"Oliveira","year":"2023","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"jrv250032r6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067113","article-title":"Why are sensory axons more vulnerable for ischemia than motor axons?","volume":"8","author":"Hofmeijer","year":"2013","journal-title":"PLoS One"},{"key":"jrv250032r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113244","article-title":"Characteristics of the nerve barrier and the blood dorsal root ganglion barrier in health and disease.","volume":"327","author":"Reinhold","year":"2020","journal-title":"Exp Neurol"},{"issue":"11","key":"jrv250032r8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1212\/WNL.0b013e31821103f7","article-title":"Neuronal intracellular transport and neurodegenerative disease.","volume":"76","author":"Staff","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"jrv250032r9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/ana.24725","article-title":"Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox?","volume":"80","author":"Loavenbruck","year":"2016","journal-title":"Ann Neurol"},{"issue":"12","key":"jrv250032r10","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.2337\/diacare.27.12.2942","article-title":"Autonomic symptoms and diabetic neuropathy: a population-based study.","volume":"27","author":"Low","year":"2004","journal-title":"Diabetes Care"},{"issue":"3","key":"jrv250032r11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ijantimicag.2017.08.033","article-title":"Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature.","volume":"51","author":"Goolsby","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"jrv250032r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152150","article-title":"Systematic review of colchicine neuromyopathy: Risk factors, duration and resolution.","volume":"58","author":"McEwan","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"jrv250032r13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0269881119882532","article-title":"Nitrous oxide causes peripheral neuropathy in a dose dependent manner among recreational users.","volume":"34","author":"Winstock","year":"2020","journal-title":"J Psychopharmacol"},{"issue":"5","key":"jrv250032r14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11940-022-00716-5","article-title":"Update on Toxic Neuropathies.","volume":"24","author":"Peters","year":"2022","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"jrv250032r15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ana.410100304","article-title":"Intensive evaluation of referred unclassified neuropathies yields improved diagnosis.","volume":"10","author":"Dyck","year":"1981","journal-title":"Ann Neurol"},{"issue":"7","key":"jrv250032r16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.mayocp.2015.05.004","article-title":"Peripheral neuropathy: a practical approach to diagnosis and symptom management.","volume":"90","author":"Watson","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"jrv250032r17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1212\/01.wnl.0000336370.51010.a1","article-title":"Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review).","volume":"72","author":"England","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"jrv250032r18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/01.wnl.0000336345.70511.0f","article-title":"Practice parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review).","volume":"72","author":"England","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"jrv250032r19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1212\/01.WNL.0000149522.32823.EA","article-title":"Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.","volume":"64","author":"England","year":"2005","journal-title":"Neurology"},{"issue":"1","key":"jrv250032r20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic neuropathy: a position statement by the American Diabetes Association.","volume":"40","author":"Pop-Busui","year":"2017","journal-title":"Diabetes Care"},{"issue":"12","key":"jrv250032r21","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/S0003-9993(98)90411-7","article-title":"Electrodiagnostic studies: are they useful in clinical practice?","volume":"79","author":"Kothari","year":"1998","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"jrv250032r22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/mus.25464","article-title":"Is electrodiagnosic testing for polyneuropathy overutilized?","volume":"55","author":"Bodofsky","year":"2017","journal-title":"Muscle Nerve"},{"issue":"2","key":"jrv250032r23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.clinph.2020.11.024","article-title":"Electrodiagnostic assessment of the autonomic nervous system: a consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology.","volume":"132","author":"Cheshire","year":"2021","journal-title":"Clin Neurophysiol"},{"issue":"6","key":"jrv250032r24","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1212\/WNL.42.6.1164","article-title":"The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity.","volume":"42","author":"Dyck","year":"1992","journal-title":"Neurology"},{"issue":"7","key":"jrv250032r25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/j.1468-1331.2010.03023.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.","volume":"17","author":"Lauria","year":"2010","journal-title":"Eur J Neurol"},{"issue":"14","key":"jrv250032r26","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1212\/WNL.0b013e3181bacf05","article-title":"Intraepidermal nerve fiber density and its application in sarcoidosis.","volume":"73","author":"Bakkers","year":"2009","journal-title":"Neurology"},{"issue":"7","key":"jrv250032r27","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ejpain.2008.07.014","article-title":"Painful or painless lower limb dysesthesias are highly predictive of peripheral neuropathy: comparison of different diagnostic modalities.","volume":"13","author":"Scherens","year":"2009","journal-title":"Eur J Pain"},{"issue":"12","key":"jrv250032r28","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1136\/jnnp-2021-328489","article-title":"Advances in diagnosis and management of distal sensory polyneuropathies.","volume":"94","author":"Silsby","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"jrv250032r29","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1212\/WNL.43.4.817","article-title":"The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.","volume":"43","author":"Dyck","year":"1993","journal-title":"Neurology"},{"key":"jrv250032r30","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.534372","article-title":"Prevalence and risk factors for diabetic peripheral neuropathy in type 2 diabetic patients from 14 countries: estimates of the INTERPRET-DD study.","volume":"8","author":"Lu","year":"2020","journal-title":"Front Public Health"},{"issue":"11","key":"jrv250032r31","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s001250050586","article-title":"Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study.","volume":"39","author":"Tesfaye","year":"1996","journal-title":"Diabetologia"},{"issue":"2","key":"jrv250032r32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212574","article-title":"The risk factors for diabetic peripheral neuropathy: a meta-analysis.","volume":"14","author":"Liu","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"jrv250032r33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jdiacomp.2013.04.003","article-title":"Obesity and hyperlipidemia are risk factors for early diabetic neuropathy.","volume":"27","author":"Smith","year":"2013","journal-title":"J Diabetes Complications"},{"key":"jrv250032r34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/B978-0-444-53480-4.00009-6","article-title":"Glucose intolerance, metabolic syndrome, and neuropathy.","volume":"126","author":"Cortez","year":"2014","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"jrv250032r35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001298","article-title":"Diabetes mellitus as a risk factor for compression neuropathy: a longitudinal cohort study from southern Sweden.","volume":"8","author":"Rydberg","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"4","key":"jrv250032r36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0299442","article-title":"Investigating the association between diabetes and carpal tunnel syndrome: a systematic review and meta-analysis approach.","volume":"19","author":"Sanjari","year":"2024","journal-title":"PLoS One"},{"key":"jrv250032r37","doi-asserted-by":"publisher","first-page":"S231","DOI":"10.2337\/dc24-S012","article-title":"12. Retinopathy, neuropathy, and foot care: standards of care in diabetes\u20142024.","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"issue":"6","key":"jrv250032r38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007543.pub2","article-title":"Enhanced glucose control for preventing and treating diabetic neuropathy.","volume":"2012","author":"Callaghan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"jrv250032r39","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ana.21952","article-title":"Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy.","volume":"67","author":"Gibbons","year":"2010","journal-title":"Ann Neurol"},{"issue":"Pt 1","key":"jrv250032r40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/brain\/awu307","article-title":"Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes.","volume":"138","author":"Gibbons","year":"2015","journal-title":"Brain"},{"issue":"9","key":"jrv250032r41","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1212\/WNL.53.9.2113","article-title":"Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy.","volume":"53","author":"Dyck","year":"1999","journal-title":"Neurology"},{"issue":"11","key":"jrv250032r42","doi-asserted-by":"publisher","first-page":"e1188","DOI":"10.1212\/WNL.0000000000007020","article-title":"Lumbosacral radiculoplexus neuropathy: incidence and the association with diabetes mellitus.","volume":"92","author":"Ng","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"jrv250032r43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004655.pub2","article-title":"Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency.","author":"Vidal-Alaball","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"jrv250032r44","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/jnnp-2017-316304","article-title":"Clinical, physiological and pathological characterisation of the sensory predominant peripheral neuropathy in copper deficiency.","volume":"88","author":"Taylor","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"jrv250032r45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1212\/01.WNL.0000132644.52613.FA","article-title":"Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration.","volume":"63","author":"Kumar","year":"2004","journal-title":"Neurology"},{"issue":"7","key":"jrv250032r46","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1212\/WNL.42.7.1367","article-title":"Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity.","volume":"42","author":"Berger","year":"1992","journal-title":"Neurology"},{"issue":"13","key":"jrv250032r47","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.3390\/nu15132823","article-title":"The role of vitamin b6 in peripheral neuropathy: a systematic review.","volume":"15","author":"Muhamad","year":"2023","journal-title":"Nutrients"},{"issue":"7-8","key":"jrv250032r48","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.nut.2008.02.022","article-title":"Rapidly developing weakness mimicking Guillain-Barr\u00e9 syndrome in beriberi neuropathy: two case reports.","volume":"24","author":"Koike","year":"2008","journal-title":"Nutrition"},{"issue":"12","key":"jrv250032r49","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1007\/s00415-018-9123-1","article-title":"Alcohol-related peripheral neuropathy: a systematic review and meta-analysis.","volume":"266","author":"Julian","year":"2019","journal-title":"J Neurol"},{"issue":"1","key":"jrv250032r50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ana.10550","article-title":"Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy.","volume":"54","author":"Koike","year":"2003","journal-title":"Ann Neurol"},{"key":"jrv250032r51","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2024.02.024","article-title":"Diagnosing peripheral neuropathy in patients with alcohol use disorder.","author":"Paul","year":"2024","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"jrv250032r52","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1212\/WNL.31.11.1480","article-title":"Prevalence of monoclonal protein in peripheral neuropathy.","volume":"31","author":"Kelly","year":"1981","journal-title":"Neurology"},{"issue":"1","key":"jrv250032r53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ana.410300111","article-title":"Neuropathy associated with monoclonal gammopathies of undetermined significance.","volume":"30","author":"Gosselin","year":"1991","journal-title":"Ann Neurol"},{"issue":"2","key":"jrv250032r54","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"issue":"13","key":"jrv250032r55","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance.","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv250032r56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1017\/S0317167100011483","article-title":"The neuropathies of Waldenstr\u00f6m\u2019s macroglobulinemia (WM) and IgM-MGUS.","volume":"38","author":"Klein","year":"2011","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"jrv250032r57","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/mus.24768","article-title":"Thrombocytosis distinguishes POEMS syndrome from chronic inflammatory demyelinating polyneuropathy.","volume":"52","author":"Naddaf","year":"2015","journal-title":"Muscle Nerve"},{"issue":"pt 5","key":"jrv250032r58","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1093\/brain\/117.5.941","article-title":"Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside.","volume":"117","author":"Kaku","year":"1994","journal-title":"Brain"},{"issue":"11","key":"jrv250032r59","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1056\/NEJM198009113031105","article-title":"Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin.","volume":"303","author":"Latov","year":"1980","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv250032r60","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1529-8027.2012.00376.x","article-title":"Heterogeneous spectrum of neuropathies in Waldenstr\u00f6m\u2019s macroglobulinemia: a diagnostic strategy to optimize their management.","volume":"17","author":"Viala","year":"2012","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"jrv250032r61","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/ana.26965","article-title":"Amyloid neuropathy: from pathophysiology to treatment in light-chain amyloidosis and hereditary transthyretin amyloidosis.","volume":"96","author":"Chompoopong","year":"2024","journal-title":"Ann Neurol"},{"key":"jrv250032r62","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jns.2017.04.015","article-title":"Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy.","volume":"377","author":"Gazzola","year":"2017","journal-title":"J Neurol Sci"},{"issue":"19","key":"jrv250032r63","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1212\/WNL.0000000000001565","article-title":"Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome.","volume":"84","author":"Karam","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"jrv250032r64","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1212\/CON.0000000000000927","article-title":"Charcot-Marie-Tooth disease and other hereditary neuropathies.","volume":"26","author":"Klein","year":"2020","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"jrv250032r65","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000443706","article-title":"Epidemiologic study of Charcot-Marie-Tooth disease: a systematic review.","volume":"46","author":"Barreto","year":"2016","journal-title":"Neuroepidemiology"},{"issue":"2","key":"jrv250032r66","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1399-0004.1974.tb00638.x","article-title":"Genetic and clinical aspects of Charcot-Marie-Tooth\u2019s disease.","volume":"6","author":"Skre","year":"1974","journal-title":"Clin Genet"},{"issue":"8","key":"jrv250032r67","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1136\/jnnp-2014-308826","article-title":"CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis.","volume":"86","author":"Fridman","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"jrv250032r68","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/jnnp-2012-302451","article-title":"Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing.","volume":"83","author":"Murphy","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"jrv250032r69","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/cge.13616","article-title":"Genetic spectrum and clinical profiles in a southeast Chinese cohort of Charcot-Marie-Tooth disease.","volume":"96","author":"Chen","year":"2019","journal-title":"Clin Genet"},{"issue":"6","key":"jrv250032r70","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/acn3.50797","article-title":"Mutation spectrum of Charcot-Marie-Tooth disease among the Han Chinese in Taiwan.","volume":"6","author":"Hsu","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"jrv250032r71","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1093\/brain\/awae064","article-title":"Whole genome sequencing increases the diagnostic rate in Charcot-Marie-Tooth disease.","volume":"147","author":"Record","year":"2024","journal-title":"Brain"},{"issue":"3","key":"jrv250032r72","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.nrleng.2024.02.008","article-title":"Clinical practice guidelines for the diagnosis and management of Charcot-Marie-Tooth disease.","volume":"40","author":"Sivera Mascaro","year":"2025","journal-title":"Neurologia (Engl Ed)"},{"issue":"5","key":"jrv250032r73","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/brain\/awab072","article-title":"RFC1 expansions are a common cause of idiopathic sensory neuropathy.","volume":"144","author":"Curr\u00f2","year":"2021","journal-title":"Brain"},{"issue":"1","key":"jrv250032r74","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv250032r75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"1","key":"jrv250032r76","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis.","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"jrv250032r77","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"jrv250032r78","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"issue":"15","key":"jrv250032r79","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy.","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"jrv250032r80","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1212\/CON.0000000000000908","article-title":"Peripheral neuropathies due to vitamin and mineral deficiencies, toxins, and medications.","volume":"26","author":"Staff","year":"2020","journal-title":"Continuum (Minneap Minn)"},{"issue":"6","key":"jrv250032r81","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/jnnp-2017-317215","article-title":"Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort.","volume":"89","author":"Shah","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"jrv250032r82","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review.","volume":"81","author":"Staff","year":"2017","journal-title":"Ann Neurol"},{"issue":"8","key":"jrv250032r83","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1001\/jamaneurol.2018.0963","article-title":"Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer: clinical, neurophysiological, functional, and patient-reported outcomes.","volume":"75","author":"Kandula","year":"2018","journal-title":"JAMA Neurol"},{"issue":"pt 3","key":"jrv250032r84","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/brain\/122.3.427","article-title":"Clinicopathological features of Churg-Strauss syndrome-associated neuropathy.","volume":"122","author":"Hattori","year":"1999","journal-title":"Brain"},{"issue":"2","key":"jrv250032r85","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"issue":"5","key":"jrv250032r86","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1212\/CON.0000000000001344","article-title":"Autoimmune axonal neuropathies.","volume":"29","author":"Tracy","year":"2023","journal-title":"Continuum (Minneap Minn)"},{"issue":"6","key":"jrv250032r87","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/archneur.61.6.914","article-title":"Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy.","volume":"61","author":"Barbano","year":"2004","journal-title":"Arch Neurol"},{"issue":"24","key":"jrv250032r88","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1212\/01.wnl.0000314647.35825.9c","article-title":"Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"issue":"12","key":"jrv250032r89","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S1474-4422(08)70228-X","article-title":"NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.","volume":"7","author":"Backonja","year":"2008","journal-title":"Lancet Neurol"},{"issue":"6","key":"jrv250032r90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub4","article-title":"Gabapentin for chronic neuropathic pain in adults.","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"jrv250032r91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007076.pub3","article-title":"Pregabalin for neuropathic pain in adults.","volume":"1","author":"Derry","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"jrv250032r92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115.pub3","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.","volume":"2014","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"jrv250032r93","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.pain.2013.05.043","article-title":"Duloxetine and pregabalin: high-dose monotherapy or their combination? the \u201cCOMBO-DN study\u201d: a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain.","volume":"154","author":"Tesfaye","year":"2013","journal-title":"Pain"},{"issue":"10353","key":"jrv250032r94","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0140-6736(22)01472-6","article-title":"Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.","volume":"400","author":"Tesfaye","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"jrv250032r95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011209.pub2","article-title":"Nortriptyline for neuropathic pain in adults.","volume":"1","author":"Derry","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"jrv250032r96","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jamaneurol.2021.0538","article-title":"Effect of high-frequency (10-khz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial.","volume":"78","author":"Petersen","year":"2021","journal-title":"JAMA Neurol"},{"issue":"5","key":"jrv250032r97","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1212\/CON.0000000000001474","article-title":"Peripheral neuropathic pain.","volume":"30","author":"Wang","year":"2024","journal-title":"Continuum (Minneap Minn)"},{"issue":"5","key":"jrv250032r98","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S1474-4422(25)00068-7","article-title":"Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis.","volume":"24","author":"Soliman","year":"2025","journal-title":"Lancet Neurol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2841552\/jama_mauermann_2025_rv_250032_1767896087.33138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:00:48Z","timestamp":1768924848000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2841552"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,1,20]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.19400","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}